Richard F Dunne1, Karen M Mustian, Jose M Garcia, William Dale, Reid Hayward, Breton Roussel, Mary M Buschmann, Bette J Caan, Calvin L Cole, Fergal J Fleming, Joe V Chakkalakal, David C Linehan, Aram F Hezel, Supriya G Mohile. 1. aWilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York bDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington cDepartment of Supportive Care Medicine, City of Hope, Duarte dSchool of Sport and Exercise Science, University of Northern Colorado, Greeley, Colorado eDepartment of Medicine, Brown University, Providence, Rhode Island fDepartment of Medicine, The University of Chicago, Chicago, Ilinois gKaiser Permanente Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Abstract
PURPOSE OF REVIEW: Cancer cachexia remains understudied and there are no standard treatments available despite the publication of an international consensus definition and the completion of several large phase III intervention trials in the past 6 years. In September 2015, The University of Rochester Cancer Center NCORP Research Base led a Symposium on Cancer Cachexia and Sarcopenia with goals of reviewing the state of the science, identifying knowledge gaps, and formulating research priorities in cancer cachexia through active discussion and consensus. RECENT FINDINGS: Research priorities that emerged from the discussion included the implementation of morphometrics into clinical decision making, establishing specific diagnostic criteria for the stages of cachexia, expanding patient selection in intervention trials, identifying clinically meaningful trial endpoints, and the investigation of exercise as an intervention for cancer cachexia. SUMMARY: Standardizing how we define and measure cancer cachexia, targeting its complex biologic mechanisms, enrolling patients early in their disease course, and evaluating exercise, either alone or in combination, were proposed as initiatives that may ultimately result in the improved design of cancer cachexia therapeutic trials.
PURPOSE OF REVIEW: Cancer cachexia remains understudied and there are no standard treatments available despite the publication of an international consensus definition and the completion of several large phase III intervention trials in the past 6 years. In September 2015, The University of Rochester Cancer Center NCORP Research Base led a Symposium on Cancer Cachexia and Sarcopenia with goals of reviewing the state of the science, identifying knowledge gaps, and formulating research priorities in cancer cachexia through active discussion and consensus. RECENT FINDINGS: Research priorities that emerged from the discussion included the implementation of morphometrics into clinical decision making, establishing specific diagnostic criteria for the stages of cachexia, expanding patient selection in intervention trials, identifying clinically meaningful trial endpoints, and the investigation of exercise as an intervention for cancer cachexia. SUMMARY: Standardizing how we define and measure cancer cachexia, targeting its complex biologic mechanisms, enrolling patients early in their disease course, and evaluating exercise, either alone or in combination, were proposed as initiatives that may ultimately result in the improved design of cancer cachexia therapeutic trials.
Authors: John E Morley; Angela Marie Abbatecola; Josep M Argiles; Vickie Baracos; Juergen Bauer; Shalender Bhasin; Tommy Cederholm; Andrew J Stewart Coats; Steven R Cummings; William J Evans; Kenneth Fearon; Luigi Ferrucci; Roger A Fielding; Jack M Guralnik; Tamara B Harris; Akio Inui; Kamyar Kalantar-Zadeh; Bridget-Anne Kirwan; Giovanni Mantovani; Maurizio Muscaritoli; Anne B Newman; Filippo Rossi-Fanelli; Giuseppe M C Rosano; Ronenn Roubenoff; Morris Schambelan; Gerald H Sokol; Thomas W Storer; Bruno Vellas; Stephan von Haehling; Shing-Shing Yeh; Stefan D Anker Journal: J Am Med Dir Assoc Date: 2011-07 Impact factor: 4.669
Authors: Karen M Mustian; Luke J Peppone; Oxana G Palesh; Michelle C Janelsins; Supriya G Mohile; Jason Q Purnell; Tom V Darling Journal: US Oncol Date: 2009
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni Journal: J Gastrointest Surg Date: 2008-03-18 Impact factor: 3.452
Authors: Jessica R Lieffers; Marina Mourtzakis; Kevin D Hall; Linda J McCargar; Carla M M Prado; Vickie E Baracos Journal: Am J Clin Nutr Date: 2009-02-25 Impact factor: 7.045
Authors: Richard F Dunne; Kah Poh Loh; Grant R Williams; Aminah Jatoi; Karen M Mustian; Supriya G Mohile Journal: Cancers (Basel) Date: 2019-11-25 Impact factor: 6.639